Arax Advisory Partners’s XBiotech XBIT Stock Holding History

Arax Advisory Partners’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15	Closed	-$35	–	5272
2026 Q1	$35	Buy	+15	New	+$36	﹤0.01%	3686
2025 Q4	–	Sell	-22	Closed	-$58	–	4572
2025 Q3	$58	Buy	+22	New	+$65	﹤0.01%	3527

Other funds holding XBIT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RBF Capital San Francisco, California $2.41B AUM 39.41% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Arax Advisory Partners's XBIT Position: Q2 2026 in Review

Arax Advisory Partners sold out of XBiotech (XBIT) in Q2 2026, closing a stake of 15 shares — an estimated $35 sold.

Arax Advisory Partners first reported a position in XBIT in Q3 2025 and held it in 2 quarters. The position peaked at $58 in Q3 2025. 36 funds tracked by Wall St. Rank hold XBIT as of Q2 2026.

Arax Advisory Partners reported no remaining XBiotech position as of Q2 2026 after selling out during the quarter.
Arax Advisory Partners sold 15 XBiotech shares in Q2 2026, an estimated $35.
Arax Advisory Partners first reported a position in XBiotech in Q3 2025 and held it in 2 quarters.
Arax Advisory Partners's XBiotech position peaked at $58 in Q3 2025.
36 funds tracked by Wall St. Rank held XBiotech as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.